Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents.
Journal: Clinical ophthalmology (Auckland, N.Z.)
Published: September 27, 2023
Early surgical displacement of submacular hemorrhage without tissue plasminogen activator use: one-year outcomes.
Journal: Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
Published: June 29, 2023
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration.
Journal: International journal of retina and vitreous
Published: October 17, 2022
Frequency and Symptoms of Intravitreal Silicone Oil Droplets Following Becton Dickinson and Norm-Ject Bevacizumab Injections.
Journal: Ophthalmic surgery, lasers & imaging retina
Published: February 11, 2022
Retinal Toxicity Associated With MEK Inhibitor Use for Metastatic Cancer: A Rising Trend in Ophthalmology.
Journal: Ophthalmic surgery, lasers & imaging retina
Published: May 17, 2016
Showing 1-5 of 5
Last Updated: 09/26/2026